Patent ID: 6333351
Filing Date: 2001-12-25
Classification: A61K

Abstract:
A pharmaceutical composition comprising a pharmaceutically inert carrier and a pharmaceutically effective amount of a compounds of formula I: ##STR11##wherein R.sup.1 is selected from the group consisting of(a) naphthyl-(R).sub.m -- wherein R is an alkylene group of from 1 to 8 carbon atoms and m is an integer equal to 0 or 1;(b) a substituted phenyl group of formula II: ##STR12##whereinR is alkylene of from 1 to 8 carbon atoms,m is an integer equal to 0 or 1,R.sup.a and R.sup.a' are independently selected from the group consisting of hydrogen, hydroxy, fluoro and methyl;R.sup.b and R.sup.b' are independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, cyano, cycloalkyl, halo, heteroaryl, heterocyclic, nitro, trihalomethyl, thioalkoxy, thioaryloxy, thioheteroaryloxy, and --C(O)R.sup.4 where R.sup.4 is selected from the group consisting of alkyl, aryl, alkoxy and aryloxy; andR.sup.c is selected from the group consisting of hydrogen, alkyl, cyano, halo, nitro, and where R.sup.b and R.sup.c are fused to form a methylenedioxy ring with the phenyl ring; andwhen R.sup.b and/or R.sup.b' and/or R.sup.c is fluoro, chloro, bromo and/or nitro, then R.sup.a and/or R.sup.a' can also be chloro;with the proviso that R.sup.a, R.sup.a', R.sup.b, R.sup.b' and R.sup.c are not all hydrogen; and(c) 1- or 2-naphthyl-(R).sub.m -- substituted at the 5, 6, 7 and/or 8 positions with 1 to 4 substituents selected from the group consisting alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy wherein R is an alkylene group of from 1 to 8 carbon atoms and m is an integer equal to 0 or 1;R.sup.2 is selected from the group consisting of alkyl, phenyl, alkylalkoxy, alkylthioalkoxy; andR.sup.3 is selected from the group consisting of --(CH.sub.2).sub.n CR.sup.10 R.sup.5 R.sup.6 wherein n is an integer equal to 0, 1 or 2, R.sup.5 and R.sup.6 are independently selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl, heterocyclic, --NR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are independently hydrogen or alkyl and --COOR.sup.9 where R.sup.9 is alkyl, and further wherein R.sup.5 and R.sup.6 can be joined to form a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group, and a heterocyclic group, and when R.sup.5 and R.sup.6 do not join to form an aryl or heteroaryl group, then R.sup.10 is selected from hydrogen and alkyl with the proviso that when n is zero, then R.sup.10 is hydrogen and where n is greater than zero and R.sup.5 and R.sup.6 are joined to from an aryl or heteroaryl group, then R.sup.10 becomes a bond within that group;X' is hydrogen, hydroxy or fluoro;X"" is hydrogen, hydroxy or fluoro, or X' and X"" together form an oxo group, andpharmaceutically acceptable salts thereof.